fr   en

Browse by date
Or search by keyword
Date: 2010-09-08
Biotech partner: Lonza (Switzerland)
Pharma Partner: GSK (UK)
Type of agreement: * manufacturing
Compound: Five monoclonal antibodies
Disease area: undisclosed
Development phase: phase 1 and 2
Nature of the agreement: GSK and Lonza have entered into a new agreement under which Lonza will support the ongoing development of GSK’s biopharmaceutical pipeline by supplying manufacturing capacity for five early stage monoclonal antibodies.
Under the terms of the agreement, Lonza will initially manufacture clinical trial batches of five compounds currently in Phase 1 and 2 for GSK. Lonza will also provide access to flexible capacity to enable GSK to respond to future demand dependent upon progression of molecules through late stage development and commercial launch.
All other details of the agreement remain confidential.

Go back to previous page